A5053141379- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Computational Drug Discovery Methods
- Mosquito-borne diseases and control
- Viral gastroenteritis research and epidemiology
- Natural Products and Biological Research
- Long-Term Effects of COVID-19
- RNA Interference and Gene Delivery
- Viral Infections and Vectors
- Viral Infections and Immunology Research
- Animal health and immunology
- MicroRNA in disease regulation
- Malaria Research and Control
National Defense Medical Center
2016-2024
The emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants has altered the trajectory COVID-19 pandemic and raised some uncertainty on long-term efficiency vaccine strategy. development new therapeutics against a wide range SARS-CoV-2 is imperative. We, here, have designed an inhalable siRNA, C6G25S, which covers 99.8% current capable inhibiting dominant strains, including Alpha, Delta, Gamma, Epsilon, at picomolar ranges IC50 in vitro. Moreover, C6G25S could...
While severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection presents with mild or no symptoms in most cases, a significant number of patients become critically ill. Remdesivir has been approved for the treatment disease 2019 (COVID-19) several countries, but its use as monotherapy not substantially lowered mortality rates. Because agents from traditional Chinese medicine (TCM) have successfully utilized to treat pandemic and endemic diseases, we designed current study...
ABSTRACT Viral RNA-dependent RNA polymerase (RdRp), a highly conserved molecule in viruses, has recently emerged as promising drug target for broad-acting inhibitors. Through Vero E6-based anti-cytopathic effect assay, we found that BPR3P0128, which incorporates quinoline core similar to hydroxychloroquine, outperformed the adenosine analog remdesivir inhibiting RdRp activity (EC 50 = 0.66 µM and 3 µM, respectively). BPR3P0128 demonstrated broad-spectrum against various severe acute...
The coronavirus disease 2019 (COVID-19) pandemic with high infectivity and mortality has caused severe social economic impacts worldwide. Growing reports of COVID-19 patients multi-organ damage indicated that acute respiratory syndrome 2 (SARS-CoV2) may also disturb the cardiovascular system. Herein, we used human induced pluripotent stem cell (iPSC)-derived cardiomyocytes (iCMs) as in vitro platform to examine consequence SARS-CoV2 infection on iCMs. Differentiated iCMs expressed primary...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causes severe “flu-like” symptoms that can progress to distress (ARDS), pneumonia, renal failure, and death. From the therapeutic perspective, 3-chymotrypsin-like protein (3CLpro) is a plausible target for direct-acting antiviral agents because of its indispensable role in viral replication. The flavonoid ugonin J (UJ) has been reported have antioxidative anti-inflammatory activities. However, potential UJ as an agent...
Drug repurposing is a fast and effective way to develop drugs for an emerging disease such as COVID-19. The main challenges of drug are the discoveries right therapeutic targets combating disease.Here, we present systematic approach, combining Homopharma hierarchal systems biology networks (HiSBiN), predict 327 21,233 drug-target interactions 1,592 FDA Among these multi-target drugs, eight candidates (along with pimozide valsartan) were tested methotrexate was identified affect 14...
On analyzing the results of cell-based assays, we have previously shown that perilla (Perilla frutescens) leaf extract (PLE), a food supplement and orally deliverable traditional Chinese medicine approved by Taiwan Food Drug Administration, effectively inhibits SARS-CoV-2 directly targeting virions. PLE was also found to modulate virus-induced cytokine expression levels. In this study, explored anti-SARS-CoV-2 activity in hamster model examining viral loads immunopathology lung tissues....
(Background) The coronavirus disease 2019 (COVID-19) that is caused by severe acute respiratory syndrome 2 (SARS-CoV-2) carries high infectivity and mortality. Efficient intervention strategies are urgently needed. Avian immunoglobulin Y (IgY) showed efficacy against viral infection whereas the in vivo remains unclear. (Methods) We immunized laying hens with S1, S1 receptor-binding domain (S1-RBD), or S2 subunits of SARS-CoV-2 spike (S) protein. After immunization, IgYs were collected...